| 1.01 0 (0%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
Thu, 15 Oct 2026
Vaccinex publishes melanoma findings: what they mean for Vaccinex stock - ad-hoc-news.de
Fri, 09 Oct 2026
Vaccinex, Inc. (VCNX) stock price, news, quote and history - Yahoo Finance UK
Thu, 30 Apr 2026
Vaccinex Reports 2025 Annual Financial Results - The Manila Times
Thu, 24 Apr 2025
VACCINEX (VCNX) Stock Price, News & Analysis - Stock Titan
Thu, 19 Dec 2024
VCNX Stock Price and Chart — OTC:VCNX - TradingView
Tue, 17 Dec 2024
Vaccinex Faces Nasdaq Delisting After Failing Minimum Equity Requirements, Moves to OTC Markets - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|